{
  "id": 18527241,
  "title": "FDA Approves Dual-Targeted Therapy for Head and Neck Cancer",
  "url": "https://urgent.news/2026/11/06/fda-approves-dual-targeted-therapy-for-head-and-neck-cancer",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-06T15:49:47.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/hematologyoncology/othercancers/123751"
  },
  "original_language": "en",
  "account": null,
  "summary": "(MedPage Today) -- The FDA granted accelerated approval to subcutaneous amivantamab and hyaluronidase (Rybrevant Faspro) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma. The approved indication is...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}